Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 16 of 27
A Study of LY2157299 Monohydrate in Healthy Volunteers
NCT01746004
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
NCT01769378
A Moderate to Severe Rheumatoid Arthritis Study
NCT01721044
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
NCT01753856
A Study of LY2940680 in Healthy Participants
NCT01746745
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
NCT01769391
A Study of LY2940680 in Small Cell Lung Cancer
NCT01722292
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
NCT01695239
A Study in Moderate to Severe Rheumatoid Arthritis Participants
NCT01721057
A Study of Evacetrapib in Healthy Participants
NCT01736254
A Study of Evacetrapib in Healthy Female Participants
NCT01746732
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
NCT01711359
A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants
NCT01725451
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
NCT01634555
A Study of LY3039478 in Participants With Advanced Cancer
NCT01695005
A Study in Moderate to Severe Rheumatoid Arthritis
NCT01710358
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
NCT01709110
A Study of Evacetrapib in High-Risk Vascular Disease
NCT01687998
A Study of LY2940680 in Healthy Participants
NCT01681186
Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)
NCT01676701
A Study of LY3015014 in Healthy Participants With High Cholesterol
NCT01671085
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
NCT01683409
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
NCT01606748
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
NCT01624467
A Study of LY3023414 in Participants With Advanced Cancer
NCT01655225
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
NCT01646177
A Study of LY3006072 in Healthy Participants
NCT01640249
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
NCT01515306
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
NCT01484431
A Study LY2228820 for Recurrent Ovarian Cancer
NCT01663857
A Study of LY2605541 Versus Insulin Glargine on Blood Sugar
NCT01654380
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
NCT01602224
A Study of Prasugrel in Healthy Participants
NCT01648790
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
NCT01567163
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
NCT01621178
A Study of IMC-TR1 in Participants With Advanced Solid Tumors
NCT01646203
A Study of LY2951742 in Participants With Migraine
NCT01625988
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
NCT01520220
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
NCT01624259
A Single Dose Study of LY3023703 in Healthy Participants
NCT01632579
A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
NCT01618916
A Multiple-dose Study of LY3031207 in Healthy Participants
NCT01632566
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
NCT01597245
A Study in Older Participants Who Have Fallen and Have Muscle Weakness
NCT01604408
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
NCT01582451
A Study of LY2127399 in Rheumatoid Arthritis
NCT01576549
A Study in Recurrent Glioblastoma (GB)
NCT01582269
A Study of LY2784544 in Healthy Male Subjects
NCT01577355
A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe
NCT01524770
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT01561430
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.